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Background The relationship between high sensitivity C-reactive protein (hs-CRP) and 
migraine is unclear. The aim of this cross-sectional population-based study was to investigate 
the association between hs-CRP and types of headache, and to evaluate the impact of 
insomnia on this association. 
Methods A total of 20,486 (63%) out of 32,591 invited aged ≥ 40 years or older participated 
in the seventh wave of the Tromsø study conducted in 2015-2016, and had valid information 
of headache, insomnia and hs-CRP. The influence of insomnia on the association between 
questionnaire-based diagnoses of headache and elevated hs-CRP defined as >3.0 mg/L was 
assessed using multiple logistic regression, estimating prevalence odds ratio (OR) with 95% 
confidence intervals (CIs).  
Results A total of 6290 participants (30.7%) suffered from headache during the last year. 
Among these, 1736 (8.5%) fulfilled the criteria of migraine, 991 (4.8%) had migraine with 
aura (MA), 746 (3.6%) migraine without aura (MO) (3.8%), and 4554 (22.2%) had non-
migrainous headache. In the final multi-adjusted analysis, elevated hs-CRP was associated 
with headache (OR 1.10, 95% CI 1.01-1.20), migraine (OR 1.17, 95% CI 1.01-1.35), and MA 
(OR 1.23, 95% CI 1.01-1.53). No association was found between elevated hs-CRP and MO or 
non-migrainous headache. The association between hs-CRP and migraine was strongly 
depended on insomnia status. Among individuals with insomnia, elevated hs-CRP was 
associated with migraine (OR 1.49, 95% CI 1.02-2.17), and MA (OR 1.59, 95% CI 1.03-
2.45), whereas no such relationship was found among those without insomnia.  
Conclusions In this cross-sectional study, participants with migraine, in particular MA, were 







Migraine is a chronic disorder with a global prevalence of approximately 15% (1) and ranked 
as the second leading cause of years lived with disability (2).   
 Migraine, particularly migraine with aura (MA), is associated with ischemic stroke (3). 
The precise mechanisms remain unclear, but a neurovascular inflammation as a part of the 
complex pathophysiological process has been suggested (4). High sensitivity C-reactive 
protein (hs-CRP), a non-specific marker of inflammation, is associated with risk of 
cardiovascular events (5). This relationship has most likely been contributing to the increasing 
focus on CRP and migraine the last decade (6-30).  
 Most previous studies evaluating the association between CRP and migraine have 
been case-control studies with small sample sizes reporting inconsistent results. Some have 
reported significant higher CRP values in migraine patients (8, 12, 13, 19, 23-27), whereas 
others have not (7, 10, 15, 16, 20, 21).  Various results have also been found in population-
based studies (9, 11, 14, 29). CRP levels were not increased in migraineurs compared to non-
migraineurs in a study from Iceland (11) or in adjusted analyses in a Dutch population-based 
case-control study (29).  In contrast, an association was found between increased CRP and 
migraine in a large cross-sectional study on women (9). An association between CRP and 
headache has also been reported in children and adolescents (14). A review of studies 
published between 2006 and 2014 indicated higher CRP levels in individuals with migraine 
than in controls (31). However, relatively few previous studies have performed analyses with 
adjustments for relevant potential confounders.  
 Insomnia may potentially modify the relationship between hs-CRP and migraine. The 




associated with higher level of CRP in a prospective study (33). However, to the best of our 
knowledge, no previous studies have explored the impact of insomnia on the relationship 
between CRP and migraine. Such approach may be of value for better understanding the 
mechanism behind a potential association between CRP and migraine.    
 The aim of the present large-scale population-based study was to evaluate the cross-
sectional association between hs-CRP and types of headache, and to investigate the impact of 
insomnia on this association. Based on previous knowledge, we hypothesized that migraineurs 
would be more likely to have elevated hs-CRP. 
 
Methods 
The Tromsø study 
The Tromsø Study is a population-based cohort study initiated in the municipality of Tromsø, 
Northern Norway. The study includes seven surveys (Tromsø 1-7) conducted between 1974 
and 2016, to which total birth cohorts and representative random samples have been invited. 
The surveys included questionnaires and interview, biological sampling and clinical 
examination.   
 
Study population 
In Tromsø 7 (2015-2016), all inhabitants aged ≥ 40 years living in Tromsø (n=32,591) were 
invited, whereof 21,083 (65%) women and men aged 40-99 years participated. Information 
about headache and insomnia were collected via questionnaires and hs-CRP was analyzed 
from non-fasting samples. The present analyses are based on data from all 20,486 participants 






Hs-CRP was analyzed at the Department of Laboratory Medicine, University Hospital of 
North Norway, Tromsø, Norway, and was assessed by a particle-enhanced 
immunoturbidimetric assay on a Modular P autoanalyzer (Roche Diagnostics, Mannheim, 
Germany) with reagents from the manufacturer with a detection limit of 0.12 mg/L (34). In 
recent population studies from the US, approximately two-thirds of Americans had serum 
CRP concentrations less than 3 mg/L, suggesting that 3 mg/L is a reasonable cut point 
between normal and elevated hs- CRP (35, 36). Thus, in the present study we replicated the 
strategy used in a previous published study from Tromsø 6 evaluating hs-CRP and cold-
pressure tolerance (34), defining normal CRP as 0-3.00 mg/L, and elevated as 3.01-20.00 
mg/L. Participants with hs-CRP values >20.00 mg/L, which may indicate acute or chronic 
disease (38), were excluded (n=116) (Fig.1). The study did not include other exclusion criteria 
than lack of response on questions about headache and insomnia. 
 
Headache 
A questionnaire screening question (“Have you suffered from headache during the last 12 
months?”) was used to identify participants with and without headache (reference group). 
 Participants who answered “yes” to the screening question completed a set of 
additional questions adapted from the third Nord-Trøndelag Health Study (HUNT3) (39), 
mainly to diagnose active migraine (i.e. during the last 12 months) according to the second 
version of the International Classification of Headache Disorders (ICHD- II) (40). Headache 
sufferers were classified as having active migraine if they fulfilled the following three criteria: 
1) Headache attacks lasting 4-72 hours (<4 hours were accepted for those who reported visual 




pulsating quality, unilateral location, moderate or severe pain intensity, and aggravation of 
physical activity and 3) During headache, at least one of the following: nausea and/or 
vomiting, or photophobia and phonophobia. Participants who fulfilled the migraine diagnosis 
and reported visual disturbance prior to headache were classified as MA, whereas the 
remaining with migraine had migraine without aura (MO). The remaining participants with 
headache were classified as having “non-migrainous headache”. The merged group of “any 
headache” consisted of participants with migraine or non-migrainous headache. 
 A question about number of headache days per months, with the following options, <1 
day, 1-6 days, 7-14 days, and more than 14 days was also available.   
 The validity of the questionnaire-based headache diagnoses has been evaluated in 
HUNT3 (39): for any headache, the sensitivity was 88 %, and specificity 86 % (kappa value 
at 0.70, 95 % CI 0.61-0.79); for migraine the sensitivity was 51 %, and specificity 95 % 
(kappa value 0.50, 95 % CI 0.32-0.68), and for MA the sensitivity was 50 %, and specificity 
95 % (kappa value 0.44, 95 % CI 0.38-0.50) (39). 
 
Insomnia  
The sleep-related questions were adapted from the validated Berge Insomnia scale (41) and 
the questionnaire-based definition of insomnia was given in accordance with DSM-V 
(Diagnostic and Statistical Manual of Mental Disorders, 5th ed.). Insomnia was defined as 1) 
Sleep disturbance for at least 3 months during the last year (“If sleep problem, how long 
time?); 2) At least 3 times per week with sleep disturbance that reduce performance at school, 
job and/or social life at least 3 times per week (“How many days per week have you felt so 
tired that it has affected your work, school or private life?”); 3) Dissatisfied with sleep at least 




least 3 times per week with duration of minimum 30 minutes having difficulty initiating 
(“How many nights per week do you usually use more than 30 minutes to fall asleep?”) 
and/or maintaining (“How many nights per week do you usually wake up for more than 30 
minutes in the middle of the night?”) and/or waking up too early (“How many nights per 
week do you usually wake up 30 minutes earlier than you wished, without being able to go 
back to sleep again? “).  
 
Covariates 
The following variables were examined as potential confounders based on previous literature 
(35, 37, 42): age (continuous); sex, years of education  (≤9, 10-12 and ≥13 years); body mass 
index (BMI) (<25, 25.0-29.9, and ≥30 kg/m2) (28, 32); smoking (current, previous, and 
never), physical activity (never, ≤ 1 time per week, ≥2 times per week), alcohol consumption 
(never, <2 times/week, ≥2times/week), self-reported diabetes (yes/no), self-reported stroke 
and/or heart infarction (yes/no), and self-reported hypertension (yes/no). Symptoms of anxiety 
and depression was measured by the 10-item questionnaire of Hopkins symptom checklist 
(HSCL-10), using mean scores of ≥1.85 as cut-off of emotional distress (43).  
 
Ethics 
This study was approved by the Regional Committee for Ethics in Medical Research 
(#2016/1997/Rek sør-øst C and #2014/940/Rek Nord), and the Norwegian Data Protection 






In the multivariate analyses, using logistic regression, we estimated the prevalence odds ratio 
(OR) with 95% confidence interval (CI) for the association between two categories of hs-CRP 
(dependent variable) and types of headache. Participants without headache were used as 
reference.  
 We initially adjusted for age and sex (model 1), and subsequently for predefined 
confounding factors. To determine which factor contributed most to the effect on the 
adjustment, analyses were carried out with adjustment for each separate factor in addition to 
age and sex. In model 2, we adjusted for age, sex and BMI. In addition, multiple factors were 
also tested together. We excluded factors from the model 3 if they did not change OR at all or 
just changed marginally (≤ 0.01) when evaluating each factor separately or by including 
several factors grouped together (i.e. self-reported diabetes, stroke/heart infarction, and 
hypertension). Potential interaction between two variables was evaluated by including the 
product of the variable in the logistic regression analyses, and the interaction was tested using 
Wald χ2 statistics. Subjects with missing data of confounding factors were included in the 
analysis to reduce the impact of possible bias.  
 To evaluate insomnia as a modifying factor on the association between CRP and types 
of headache, we repeated the multi-adjusted analyses in model 3, separating by insomnia 
status. 







As demonstrated in Table 1, individuals with headache were more likely to be women, 
younger, and had worse health compared to those without headache.  
 
Prevalence of headache 
A total of 6290 (30.7%) participants suffered from headache during the last year, 1736 (8.5%) 
fulfilled the criteria of migraine, 991 (4.8%) had migraine with aura (MA), 746 (3.6%) 
migraine without aura (MO) (3.8%), and 4554 (22.2%) had non-migrainous headache. 
 
The association between elevated hs-CRP and headache 
In the multivariate analyses, adjusting for age and sex, elevated hs-CRP was associated with 
headache (OR 1.19, 95% CI 1.09-1.30), migraine (OR 1.24, 95% CI 1.07-1.49), and MA (OR 
1.38, 95% CI 1.16-1.64), whereas there were no clear association was found between elevated 
hs-CRP and MO or non-migrainous headache (Table 2). In the final model 3, adjusting for all 
confounding factors, elevated hs-CRP was still significant associated with headache (OR 
1.10, 95% CI 1.01-1.20), migraine (OR 1.17, 95% CI 1.01-1.35), and MA (OR 1.23, 95% CI 
1.01-1.53) (Table 2).  
Although no interaction was observed, the impact of headache frequency was evaluated. In 
age- and sex-adjusted analyses somewhat stronger association with elevated hs-CRP was 
found for individuals with headache ≥ 7 days/month than for those with headache less than 7 
days/month (Table 2). In the final multi-adjusted analyses, elevated hs-CRP was associated 
with migraine ≥ 7 days/month (OR 1.21, 95% CI 1.01-1.46), but not migraine less than 7 





The impact of insomnia  
A significant interaction between insomnia status and types of headache was found (p<0.003). 
Table 3 shows fully adjusted analyses separating by insomnia status. A total of 1669 (8.1%) 
participants fulfilled the DSM-V criteria of insomnia. Among these, elevated hs-CRP was 
significant associated with migraine (OR 1.49, 95% CI 1.02-2.17) and MA (OR 1.59, 95% CI 




In this population-based cross-sectional study, participants with migraine, in particular MA, 
were more likely to have elevated hs-CRP (between >3-20 mg/L), evident only among those 
with insomnia. 
 
Comparison with other population-based studies 
In accordance with our results, the Women Health study showed that women with migraine 
were more likely to have CRP 4.2 mg/l or above (OR 1.13, 95% CI 1.05-1.22) than women 
without migraine (9).  Furthermore, among children and adolescents aged 4-19 years, those 
being in the highest CRP quintile was associated with headache (OR 1.23, 95% CI 1.00-1.51) 
(14). In the Dutch case-control study (29), greater than median value was defined as elevated 
hs-CRP. In the unadjusted analyses, MA were more likely to have elevated hs-CRP (1.74, 
95% CI 1.09-2.78), and borderline elevated in the multi-adjusted model (OR 1.60, 95% CI 




to non-migraineurs (11). It should be noted that the Reykjavik study excluded subjects with 
CRP values above 10 mg/L (11), whereas the exclusion cut-off was above 20 mg/L in the 
present study.  
In accordance with the Dutch study (29), MA was most consistently associated with elevated 
hs-CRP in the present study. We did not find any association with MO. By reviewing 
previous studies, a consistent stronger association in MA than MO has not been demonstrated 
(31). However, in the Dutch study the average number of aura attacks and total number of 
years of aura were both found to associated with hs-CRP (29). Correspondingly,  in the 
present study the highest OR for having elevated hs-CRP was found for individuals with 
migraine at least 7 days/month.  
 To the best of our knowledge, no previous study has evaluated insomnia as a 
modifying factor on the association between CRP and migraine or included insomnia as one 
of the confounding factor. Interestingly, we found that the significant association between 




If there is a causal link between hs-CRP, ischemic cardiovascular disease, and migraine, a 
stronger relationship between elevated hs-CRP and MA should be expected, because a 
relationship with ischemic cardiovascular disease is most evident for MA (3). On the other 
hand, the present results could represent an epiphenomenon, not specific for migraine (31). 
Based on our results, one may speculate that insomnia may be of major importance on the 
relationship between CRP and migraine. Possibly, migraine, insomnia and elevated hs-CRP 
may share a common underlying factor, e.g. related to endothelial function. However, this 




endothelial function measured by flow-mediated dilatation and insomnia (44) or migraine (45) 
in population-based studies. In future studies evaluating the association between CRP and 
migraine, the influence of insomnia should be considered.  
 
Strengths and limitations of the study 
The major strengths of this study are the population-based design and the possibility to 
perform adjustments for important potential confounding factors. However, the possibility of 
residual confounding by an unrecognized factor cannot be ruled out. The participation rate 
(65%) was good, but generalization of results should be performed with caution. Finally, the 
diagnosis of insomnia in this study was in accordance with the current DSM-V criteria of 
insomnia.  
Several study limitations should also be considered. Firstly, the cross-sectional design does 
not permit any conclusions about causality. Secondly, the diagnoses of headache and 
insomnia were questionnaire-based, which may have led to misclassification. However, the 
questionnaire-based diagnosis of migraine has previously shown acceptable agreement with 
corresponding diagnosis in a clinical interview (39). MA diagnosis was based on one question 
about visual disturbance before headache, with high specificity, but low sensitivity (39). 
Ideally, more details about the aura symptoms had been informative, e.g. the proportion of 
migraine attacks which were accompanied by aura. The sleep-related questions were adapted 
from the Bergen Insomnia Scale, which has previously been validated against the DSM-IV 
criteria for insomnia (41). The DSM-V criteria of insomnia is somewhat different from other 
recent population-based studies that either have used the older DSM-IV definition of 
insomnia (46) or studies which have operationalized the ICDS-3 criteria for insomnia 
considering dissatisfaction with sleep quality or sleep length not mandatory for the diagnosis 




dissatisfaction with sleep as a mandatory criterion for the definition of insomnia.  
 
Conclusions 
In this population-based cross-sectional study, participants with migraine, in particular MA, 
were more likely to have elevated hs-CRP, evident only among those with insomnia.  
 
Clinical implications 
 Participants with migraine, in particular migraine with aura, were more likely to have 
elevated hs-CRP  
 The association between elevated hs-CRP and migraine was only found among 
participants with insomnia.  
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Table 1 Characteristics of participants (n=20,486) in the Tromsø Study 2015-2016 according to types of headache. 
 No headache  Any headache MA MO Non-migrainous headache 
Participants, n 14,196 6,290 991 745 4554 
Women, n (%) 6637 (46.8) 4137 (65.8) 755 (76.2) 589 (79.1) 2793 (61.3) 
Mean age, years (SD) 58.8 (11.6) 53.5 (9.9) 52.3 (9.2) 50.5 (7.9) 54.3 (10.2) 
Age ≥ 60 years (%) 6656 (46.9) 1643 (26.1) 212 (21.4) 102 (13.7) 1329 (29.2) 
Education > 12 years, n (%) (missing=343) 6867 (48.4) 3096 (49.2) 469 (47.3) 433 (58.1) 2194 (48.2) 
Current daily smoking, n (%) (missing=179) 1849 (13.0) 971 (15.4) 171 (17.3) 79 (10.6) 721 (15.8) 
Mean BMI, kg/m2 (SD) (missing=55) 27.3 (4.4) 27.5 (4.8) 27.6 (5.2) 26.9 (4.8) 27.6 (4.7) 
Mean HSCL-10 (SD) (missing=137) 1.2 (0.3) 1.4 (0.5) 1.6 (0.6) 1.4 (0.5) 1.4 (0.4) 
Alcohol abstainers, n (%) (missing=121) 1021 (7.2) 571 (9.1) 118 (11.9) 65 (8.7) 388 (8.5) 
Physical inactivity, n (%) (missing=70) 581 (4.1) 227 (3.6) 38 (3.8) 22 (3.0) 167 (3.7) 
Self-reported hypertension, n (%)   2811 (19.8) 1064 (16.9) 158 (15.9) 82 (11.0) 824 (18.1) 
Self-reported stroke and/or heart infarction (%) 932 (6.6%) 237 (3.8%) 34 (3.4) 17 (2.3) 186 (4.1) 
Self-reported diabetes mellitus, n (%)  698 (4.9) 254 (4.0) 41 (4.1) 20 (2.7) 193 (4.2) 
DSM-V insomnia, n (%)   753 (5.3) 916 (14.6) 205 (20.7) 125 (16.8) 586 (12.9) 
Mean hs-CRP (95% CI) 1.7 (1.6-1.7) 1.7 (1.7-1.8) 1.8 (1.7-1.9) 1.6 (1.5-1.8) 1.7 (1.7-1.8) 
MA=migraine with aura; MO=Migraine without aura; HSCL= Hopkins Symptom Checklist 10-item version; BMI=body mass index; hs-CRP=high sensitivity C-reactive protein; CI= Confidence intervals; DSM-






Table 2. Odds ratio (OR) with 95% confidence interval (CI) of C-reactive protein (CRP) defined as >3.0-20.0 mg/l according type of headache 
   High CRP  Model 1  Model 2 Model 3 
 Total   N OR (95% CI)  OR (95% CI) OR (95% CI) 
No headache 14,196  2044 1.00   1.00  1.00  
Any headache 6,290  990 1.19 (1.09-1.30)  1.14 (1.04-1.25) 1.10 (1.01-1.20) 
<7 days/month 4936  761 1.17 (1.06-1.28)  1.13 (1.02-1.24) 1.10 (0.99-1.21) 
≥ 7 days/month 1354  229 1.28 (1.10-1.24)  1.19 (1.02-1.24) 1.09 (0.93-1.28) 
Migraine  1736  277 1.24 (1.07-1.49)  1.12 (1.02-1.40) 1.17 (1.01-1.35) 
< 7 days/month 1294  198 1.18 (1.00-1.39)  1.15 (0.97-1.77) 1.14 (0.96-1.35) 
≥ 7 days/month 442  79 1.44 81.12-1.86)  1.40 (1.08-1.87) 1.22 (1.01-1.46) 
MA  991  175 1.38 (1.16-1.64)  1.29 (1.08-1.55) 1.23 (1.01-1.53) 
< 7 days/month 719  123 1.36 (1.11-1.67)  1.28 (1.04-1.58) 1.31 (0.94-1.81) 
≥ 7 days/month 272  52 1.53 (1.13-2.09)  1.45 (1.05-1.99) 1.32 (0.95-1.82) 
MO 745  102 1.05 (0.84-1.30)  1.08 (0.86-1.35) 1.08 (0.86-1.36) 
< 7 days/month 580  75 1.01 (0.79-1.30)  1.04 (0.80-1.35) 1.05 (0.81-1.37) 
≥ 7 days/month 165  27 1.32 (0.74-2.01)  1.35 (0.84-2.07) 1.34 (0.87-2.07) 
Other headaches 4554  713 1.17 (1.07-1.29)  1.12 (1.01-1.24) 1.07 (0.97-1.19) 
< 7 days/month 3642  563 1.17 (1.06-1.30)  1.13 (1.01-1.26) 1.10 (0.99-1.23) 





MA=migraine with aura; MO=Migraine without aura.                                                                                                                                                                                        
Model 1: Adjusted for ag, and sex.                                                                                                                                                                                                                       
Model 2: Adjusted for age, sex and body mass index.                                                                                                                                                                                         




Table 3. Multi-adjusted* odds ratio (OR) with 95% confidence interval (CI) of elevated C-reactive protein (CRP) defined as >3.0-20.0 mg/l 
according to type of headache separated by insomnia status 
     No insomnia   Insomnia 
 Total   N OR (95% CI)  N OR (95% CI) 
No headache 14,196  13,443 1.00   753 1.00  
Any headache 6,290  5,374 1.06 (0.97-1.17)  916 1.32 (0.99-1.76) 
Migraine  1736  1,406 1.10 (0.93-1.30)  330 1.49 (1.02-2.17) 
MA  991  786 1.15 (0.93-1.41)  205 1.59 (1.03-2.45) 
MO 745  620 1.03 (0.80-1.33)  125 1.31 (0.75-2.28) 
Other headaches 4554  3,968 1.05 (0.95-1.17)  586 1.25 (0.91-1.70) 
* Adjusted for age, sex, body mass index, smoking, education level, alcohol use, physical activity and anxiety and depression measured by Hopkins Symptom Checklist                                                                                             














Figure 1. Flow chart of participation in Tromsø Study 2015-2016 
  
  
                                






































hs-CRP missing: 106      
hs-CRP>20 mg/l: 116 
